Ascendia

25 Year BadgeDrug Development & Delivery Celebrates 25 Years!

For a quarter century, Drug Development & Delivery has connected innovators, scientists, and industry leaders while spotlighting the technologies and ideas shaping the future of the industry. We celebrate 25 years of advancing the conversation!

  MARKET NEWS

Novo Nordisk Launches ‘Novo’ Rebrand to Sharpen Global Identity
Xeris Taps medmix Pen Platform for Once-Weekly Levothyroxine Program
Lonza to Add Commercial Spray-Drying Capacity at Oregon Manufacturing Site
Smart Gel May Pave Way for Next-Gen Drug Delivery
Novartis Reassesses Del-desiran Program After Phase III DM1 Study Misses Primary Endpoint
Revvity Expands Human-Relevant Cell Model Capabilities With Human Cell Design Acquisition

  EXPERT CONTENT & RESOURCES

 

John Jansen

Managing Fragmented Small-Molecule Supply Chains Through Strategic Secondary Bulk Packaging

As small-molecule manufacturing becomes increasingly fragmented across regions, specialist facilities, and CDMOs, every product handoff introduces new opportunities for delay and variability. A strategic bulk secondary packaging approach can help standardize product handling, improve operational control, and strengthen resilience across complex pharmaceutical supply chains.

Abbvie Logo

Four Myths About Embedded CMOs, Busted

Are your perceptions of the CMO marketplace serving your drug program—or holding it back? If you’re looking for a contract manufacturer to bring your therapy to market, you’re far from alone. Demand for manufacturing services is shaping the pharma Contract Manufacturing Industry, with analysts predicting a growth rate of nearly 7% per year until 2028. In such a competitive market, how should a project sponsor navigate the choice between one CMO and another? To find the answer, many sponsors begin by distinguishing between typical stand-alone CMOs and an embedded CMO that operates under a parent company—AbbVie, in the case of AbbVie Contract Manufacturing (AbbVie).

Dr. Anjali Shah

How Molecular Biology Technologies Are Transforming Discovery and Development

Advances in PCR, sequencing, automation, and molecular analysis are helping biopharma teams accelerate discovery, improve data quality, and reduce development risk. Thermo Fisher Scientific’s Dr. Anjali Shah discusses how integrated molecular biology workflows are evolving to support increasingly complex therapeutic modalities.

  FEATURED EDITORIAL

  EXPERT INSIGHTS VIDEOS

The Future of Injection Devices: Key Trends Shaping Drug Delivery

The Future of Injection Devices: Key Trends Shaping Drug Delivery

  COMPANY PROFILE

Resilience is a North American contract development and manufacturing organization (CDMO) focused on delivering high-quality, scalable manufacturing solutions for advanced therapies. With capabilities spanning biologics drug substance, cell-based therapies, and aseptic drug product manufacturing for both small and large molecules, Resilience partners with leading biopharma companies to bring complex medicines to market faster and more reliably.

Click here for more.

 

  WHITEPAPERS & WEBINARS

WHITEPAPER - Streamlined Product Development Leveraging Pharmaceutical Classification Models

WHITEPAPER - Streamlined Product Development Leveraging Pharmaceutical Classification Models

A technology agnostic approach based on a fundamental understanding of API properties, a well-defined yet flexible target product profile, and a mindset for scalability and commercial relevance leads to success in formulation development and drug product design.

In this whitepaper, …

WEBINAR ON DEMAND - Heat Without Harm: The Reality of Hot Melt Extrusion Webinar

WEBINAR ON DEMAND - Heat Without Harm: The Reality of Hot Melt Extrusion Webinar

In a 2025 industry survey (1), 76% of respondents selected ‘risk of thermal degradation’ as a source of hesitation to pursue hot melt extrusion (HME). Concerns about heat-sensitive APIs frequently lead development teams to rule out HME early — …

WEBINAR ON DEMAND: Why early matters: Data-driven strategies to de-risk OSD development

WEBINAR ON DEMAND: Why early matters: Data-driven strategies to de-risk OSD development

Late-stage surprises continue to drive cost, delay, and challenges in oral solid dosage (OSD) development—especially for complex, poorly soluble molecules. Too often, formulation and manufacturability risks surface only after significant time and investment.

In a recent panel discussion, GlobalData’s Director …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

September 23 – Analytical Testing
September 30 – Formulation Development
October 7 – Prefilled Syringes
October 14 – Injection Devices
October 21 – Transdermal/Topical Delivery
October 28 – Formulation Development